Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GS-9350-boosted atazanavir versus ritonavir-boosted atazanavir with Truvada in treatment-naive adults with HIV-1
NL-OMON38379Phase 3Active, not recruiting
- Sponsor
- Gilead Sciences
- Start
- Oct 2010
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of cobicistat, ritonavir, atazanavir, emtricitabine and tenofovir disoproxil fumarate in Human immunodeficiency virus infection type 1 (2 arms), sponsored by Gilead Sciences. Primary endpoint: Week 48 virologic suppression. Started Oct 2010; status: active, not recruiting.
02
Drugs
cobicistatritonaviratazanaviremtricitabinetenofovir disoproxil fumarate
03
Conditions
Human immunodeficiency virus infection type 1
Beyond the preview
Go deeper on NL-OMON38379.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON38379.